Praecis makes prostate submission

Published: 3-Feb-2001


Praecis has submitted an NDA with the FDA for the prostate cancer treatment abarelix depot. This first-in-class drug avoids stimulating the secretion of testosterone, the hormone implicated in most prostate cancers. The company is also investigating the drug for the treatment of endometriosis.

You may also like